Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (kupffer cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: bemarituzumab, imgatuzumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 525 | 0.91 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 9624
Sealed predictions
- FCGR3A in dopamine neurons, braak+0.12 (p 0.759) → +0.05 (p 0.894)receipt 9631
Swarm cases
receipt 9631: FCGR3A in dopamine neurons, braak
- power
- full sample +0.08 (p 0.767, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.11 (p 0.664, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.591, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.24, sign flips 3; without severely affected donors +0.08 (p 0.767, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FCGR3A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts